カテゴリ： GlobalData, アメリカ, 企業調査

Eli Lilly and Co (LLY)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Eli Lilly and Co (LLY) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7240
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：103
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline products. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes its products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co (LLY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eli Lilly and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eli Lilly and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Eli Lilly and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Eli Lilly and Co, Medical Equipment, Deal Details 12
Asset Purchase 12
Eli Lilly Acquires Rights to Intranasal Glucagon from Locemia Solutions 12
Eli Lilly Acquires Two Alzheimer’s Disease Imaging Agents From Siemens Medical Solutions 13
Venture Financing 14
EdiGene Raises USD15 Million in Pre-Series B Venture Financing 14
Rimidi Raises USD6.6 Million in Series A-1 Financing 15
Avedro Raises USD25 Million in Venture Financing 16
Veritas Genetics Raises USD30 Million in Series B Financing 18
Millin Enterprises Raises Funds through Series A financing 19
ACEA Biosciences Raises USD30 Million in Venture Financing 20
Microtech Medical Raises Funds through Series A Financing 21
Veritas Genetics Raises USD10 Million in Series A Financing Round 22
Companion Medical Raises USD3.15 Million in Series B Financing 23
Private Equity 24
Lilly Asia Ventures and HighLight Capital Invests USD77 Million in Sansure Biotech 24
Partnerships 25
Eli Lilly and Livongo Health Enter into Partnership 25
Eli Lilly and Co Enters into Co-Development Agreement with Rimidi Diabetes 26
DexCom Enters into Agreement with Eli Lilly 27
Insulet Enters into Co-Development Agreement with Eli Lilly 28
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 29
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 30
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 31
Corgenix Enters Into Co-Development Agreement With Eli Lilly 32
Insulet Enters Into Co-Development Agreement With Eli Lilly 33
Qiagen Enters Into Co-Development Agreement With Eli Lilly 34
Dako Enters Into Agreement With Eli Lilly To Develop Companion Diagnostic Tests 35
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 36
Cardinal Health Enters Into Co-Marketing Agreement With Eli Lilly For Amyvid 37
Eli Lilly Enters into Licensing Agreement with Transcriptic 38
Equity Offering 39
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 39
Eli Lilly and Co – Key Competitors 41
Eli Lilly and Co – Key Employees 42
Eli Lilly and Co – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 52
Recent Developments 53
Strategy And Business Planning 53
Sep 07, 2017: Lilly Takes Steps To Streamline Business, Invest In New Medicines And Drive Growth 53
Financial Announcements 54
Jul 24, 2018: Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance 54
Apr 24, 2018: Lilly Reports First-Quarter 2018 Financial Results 57
Jan 31, 2018: Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance 62
Dec 13, 2017: Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020 68
Oct 24, 2017: Lilly Reports Third-Quarter Results 2017 69
Jul 25, 2017: Lilly Reports Second-Quarter Results 74
Apr 25, 2017: Lilly Reports First-Quarter 2017 Results 78
Jan 31, 2017: Lilly Reports Fourth-Quarter And Full-Year 2016 Results 82
Corporate Communications 88
May 23, 2018: Eli Lilly and Company Announces Retirement Of Sue Mahony As President Of Lilly Oncology 88
Mar 09, 2018: Maura Dickler, M.D. To Become Vice President Of Late Phase Development At Lilly Oncology 89
Dec 11, 2017: Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology 90
Nov 13, 2017: Lilly Appoints Philip Johnson to Senior Vice President and Treasurer 91
Sep 29, 2017: Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing 92
Jun 01, 2017: Derica Rice To Retire As Lilly Chief Financial Officer 93
May 10, 2017: Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications 94
Mar 02, 2017: Lilly Announces Changes In Senior Management 95
Feb 09, 2017: Carolyn R. Bertozzi, Ph.D., Elected To Lilly Board Of Directors 96
Legal and Regulatory 97
Aug 30, 2018: Adocia announces update to second arbitration against Eli Lilly & Company 97
Government and Public Interest 98
Apr 04, 2017: Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students 98
Other Significant Developments 99
Sep 25, 2017: Geisinger And Boehringer Ingelheim Collaborate To Create A Predictive Model To Help Improve Health Outcomes For People With Type 2 Diabetes 99
Jun 21, 2017: Eli Lilly And Company Unveils Expanded Biotechnology Center In San Diego 100
May 17, 2017: Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform 101
Jan 05, 2017: Lilly To Adjust Organization And Leadership Structure To Better Align With Growth Opportunities 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103

List of Tables
Eli Lilly and Co, Medical Equipment, Key Facts, 2017 2
Eli Lilly and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eli Lilly and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eli Lilly and Co, Deals By Market, 2012 to YTD 2018 9
Eli Lilly and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Eli Lilly Acquires Rights to Intranasal Glucagon from Locemia Solutions 12
Eli Lilly Acquires Two Alzheimer's Disease Imaging Agents From Siemens Medical Solutions 13
EdiGene Raises USD15 Million in Pre-Series B Venture Financing 14
Rimidi Raises USD6.6 Million in Series A-1 Financing 15
Avedro Raises USD25 Million in Venture Financing 16
Veritas Genetics Raises USD30 Million in Series B Financing 18
Millin Enterprises Raises Funds through Series A financing 19
ACEA Biosciences Raises USD30 Million in Venture Financing 20
Microtech Medical Raises Funds through Series A Financing 21
Veritas Genetics Raises USD10 Million in Series A Financing Round 22
Companion Medical Raises USD3.15 Million in Series B Financing 23
Lilly Asia Ventures and HighLight Capital Invests USD77 Million in Sansure Biotech 24
Eli Lilly and Livongo Health Enter into Partnership 25
Eli Lilly and Co Enters into Co-Development Agreement with Rimidi Diabetes 26
DexCom Enters into Agreement with Eli Lilly 27
Insulet Enters into Co-Development Agreement with Eli Lilly 28
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 29
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 30
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 31
Corgenix Enters Into Co-Development Agreement With Eli Lilly 32
Insulet Enters Into Co-Development Agreement With Eli Lilly 33
Qiagen Enters Into Co-Development Agreement With Eli Lilly 34
Dako Enters Into Agreement With Eli Lilly To Develop Companion Diagnostic Tests 35
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 36
Cardinal Health Enters Into Co-Marketing Agreement With Eli Lilly For Amyvid 37
Eli Lilly Enters into Licensing Agreement with Transcriptic 38
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 39
Eli Lilly and Co, Key Competitors 41
Eli Lilly and Co, Key Employees 42
Eli Lilly and Co, Subsidiaries 44
Eli Lilly and Co, Joint Venture 52

List of Figures
Eli Lilly and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eli Lilly and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eli Lilly and Co, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Eli Lilly and Co (LLY)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AltaGas Ltd.：企業の戦略・SWOT・財務分析
    AltaGas Ltd. - Strategy, SWOT and Corporate Finance Report Summary AltaGas Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Pentair plc (PNR)-エネルギー分野：企業M&A・提携分析
    Summary Pentair plc (Pentair) is an industrial manufacturing company. It designs, manufactures and markets water system products and solutions for filtration, separation and fluid process management; and products that guard sensitive electrical and electronic equipment; and heat management solutions …
  • Semiconductor Manufacturing International Corporation
    Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report Summary Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Pebblebrook Hotel Trust：企業のM&A・事業提携・投資動向
    Pebblebrook Hotel Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pebblebrook Hotel Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Mobile Telesystems：企業の戦略・SWOT・財務情報
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Lotus Bakeries NV：企業の戦略・SWOT・財務情報
    Lotus Bakeries NV - Strategy, SWOT and Corporate Finance Report Summary Lotus Bakeries NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • MedX Health Corp (MDX)：医療機器：M&Aディール及び事業提携情報
    Summary MedX Health Corp (MedX) is a medical device company that designs, manufactures and distributes phototherapeutic devices. The company’s phototherapy products include rehab laser console system, acupuncture portable laser console system, rehab portable laser, oralase portable laser probe, and …
  • Suzuki Motor Corp (7269)：企業の財務・戦略的SWOT分析
    Suzuki Motor Corp (7269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nippon Soda Co Ltd (4041)：企業の財務・戦略的SWOT分析
    Nippon Soda Co Ltd (4041) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tamir Biotechnology Inc-製薬・医療分野：企業M&A・提携分析
    Summary Tamir Biotechnology Inc (Tamir Biotechnology), formerly Alfacell Corp is a clinical stage antiviral therapeutics company that discovers and develops prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions. The company’s targets include human papillom …
  • Tree Top, Inc.：企業の戦略・SWOT・財務分析
    Tree Top, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tree Top, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Hour Glass Ltd (AGS)：企業の財務・戦略的SWOT分析
    The Hour Glass Ltd (AGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Google LLC：企業の戦略的SWOT分析
    Google LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • BaroFold Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary BaroFold Inc (BaroFold) is a biotechnology company that provides protein herapeutics for bio-pharmaceutical companies, research institutions, and government agencies. The company applies its Pressure Enabled Protein Manufacturing (PreEMT) technology that improves the tolerability, efficacy a …
  • Samyang Holdings Corp (000070)：企業の財務・戦略的SWOT分析
    Summary Samyang Holdings Corp (Samyang) is a holding company engaged in the development and manufacture of food, pharmaceutical and chemical products. The company produces chemicals such as terephthalic acid, engineering plastics, organic chemicals, resins and other specialty chemicals; food materia …
  • Canadian Western Bank Group (CWB)：企業の財務・戦略的SWOT分析
    Canadian Western Bank Group (CWB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Fidelity Investments Inc：企業のM&A・事業提携・投資動向
    Fidelity Investments Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fidelity Investments Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Indigo Biosciences Inc-製薬・医療分野：企業M&A・提携分析
    Summary Indigo Biosciences Inc (Indigo) is a provider of preclinical contract research services for pharmaceutical research and development, biotechnology sectors. The company’s products include assay kit platforms and formats, nuclear receptor, signaling pathway, and cell viability assay products, …
  • Stater Bros. Markets：企業の戦略・SWOT・財務情報
    Stater Bros. Markets - Strategy, SWOT and Corporate Finance Report Summary Stater Bros. Markets - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ChemRar High-Tech Center：製薬・医療：M&Aディール及び事業提携情報
    Summary ChemRar High-Tech Center (CHTC) is a developer of drugs for life-threatening diseases. The company offers drugs for the treatment of cancer, central nervous system, infectious, metabolic and cardiovascular diseases. It also offers pre-clinical and clinical research of new molecules including …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆